U.S. markets closed

CHF Solutions, Inc. (CHFS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2923+0.0002 (+0.07%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.2921
Open0.2900
Bid0.2852 x 1000
Ask0.2950 x 900
Day's Range0.2800 - 0.2930
52 Week Range0.2800 - 1.9000
Volume4,220,176
Avg. Volume11,599,987
Market Cap23.991M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-1.2480
Earnings DateAug 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    CHF Solutions to Share COVID-19 Experience with Leading Government Commission

    EDEN PRAIRIE, Minn., Sept. 23, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to improving the lives of patients suffering from fluid overload conditions, today announced it will be providing testimony to the U.S. International Trade Commission (USITC) concerning the availability of U.S.-sourced medical supplies to treat COVID-19 and future pandemics. USITC is highly regarded across the U.S. and the world as an independent, nonpartisan, quasi-judicial federal agency that fulfills a range of trade-related mandates. Under its mandate, USITC provides detailed analysis of international trade issues to the President and the Congress, and it serves as the forum for the adjudication of intellectual property and trade disputes.On August 13, 2020, two Congressional committees – the House Committee on Ways and Means and the Senate Committee on Finance – jointly issued a formal request to USITC calling on it to further its investigation into COVID-19 related supply chain challenges and to submit its findings in a report to Congress. This report is widely anticipated to aid Congress in making what the committees term “critical policymaking decisions” concerning U.S. COVID-related industry sectors, including the medical device industry.On Wednesday, September 23, 2020, USITC will hear from industry experts, including Nestor Jaramillo, President and Chief Operating Officer of CHF Solutions. In his testimony, Mr. Jaramillo will focus on the need for medical supply security in the U.S., and he will offer CHF Solutions as an example of how U.S.-sourced solutions can rapidly scale to meet critical needs, such as those arising during pandemics like COVID-19.“CHF Solutions is grateful for the opportunity to participate in USITC’s hearing, and we are honored that our President and Chief Operating Officer, Nestor Jaramillo, will be speaking with USITC Commissioners about our experience and recommendations,” said John Erb, CEO of CHF Solutions. “Our team works hard every day to deliver the Aquadex SmartFlow™ system, a state-of-the-art solution that aids specialists caring for patients suffering fluid overload. It is deeply gratifying for our team’s efforts to be recognized in such an important and impactful setting.”When COVID-19 struck, frontline medical teams quickly realized the pandemic was causing many patients to suffer a complication known as hypervolemia, an overload of fluids resulting from cardiac or renal dysfunction. Unless addressed, hypervolemia causes COVID-19 patients to face a much higher risk of dying due to fluid in their lungs, respiratory failure, kidney injury and failure, septic shock, and multi-system organ failure.Aquadex™ therapy has been deployed in COVID-19 frontline hospitals as an adjunct therapy for patients afflicted by the pandemic, enabling physicians to treat volume overload before patients succumbed to the ravages of hypervolemia. At the same time, the Aquadex systems also enabled frontline hospitals to free up dialysis equipment and supplies, both of which experienced extreme shortages in COVID-19 hot spots.“We are proud of the clinical outcomes the Aquadex system is helping to make possible,” continued John Erb, “and we recognize this progress may have been impossible but for Aquadex’s domestic production, supply, and servicing. The COVID-19 pandemic produced an unanticipated demand for our device and support. Because CHF Solutions manufactures, services, and supplies Aquadex entirely in the United States, we were able to leverage our domestic presence to scale rapidly and meet demand, even as the COVID-19 pandemic was posing serious challenges to international trade. Were Aquadex foreign sourced, I simply do not know if we would have been able to scale up, meet demand, and enable frontline care teams to save their patients from this devastating virus.”Policy consensus is forming in Washington, D.C. that medical supply security may only be realized in the U.S. if the domestic manufacture of essential medications, medical devices, and protective equipment is established, nurtured, and supported. Towards that end, federal and state decision makers are giving priority consideration to coverage, regulatory, and related policies that may encourage and sustain domestic sources of the medical items and services the U.S. is likely to need during COVID-19 and future pandemics.The Aquadex SmartFlow system is produced in Minnesota and is used as an adjunct therapy for fluid management by COVID-19 frontline hospitals, especially when dialysis equipment and staff are limited. As recently cited, isolated ultrafiltration has proven to be an optimal strategy that primarily focuses on fluid extraction and optimization of volume status.1 A portable ultrafiltration device with small extracorporeal volume (i.e. 35 ml), the Aquadex SmartFlow system provides a predictable method for fluid extraction, making it more likely to achieve precise fluid balance in COVID-19 patients.1 https://pubmed.ncbi.nlm.nih.gov/32336959/About CHF Solutions CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.About the Aquadex SmartFlow System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the testimony to be presented to the U.S. International Trade Commission, the outcome of the report from the U.S. International Trade Commission, and supply security provided by domestic manufacturing. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our expectations regarding the potential impacts of the COVID-19 pandemic on our business operations, our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. CONTACT: CONTACTS INVESTORS: Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.com MEDIA: Jessica Stebing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com

  • GlobeNewswire

    CHF Solutions to Participate at Lake Street Capital Markets’ 4th Annual BIG4 Conference on September 17, 2020

    EDEN PRAIRIE, Minn., Sept. 11, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the company will participate in Lake Street Capital Markets’ 4th Annual Best Ideas Growth Conference, being held virtually.  Nestor Jaramillo, President and Chief Operating Officer, and Claudia Drayton, Chief Financial Officer, will be holding one-on-one meetings with investors on Thursday, September 17, 2020. About CHF Solutions CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow™ system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.About the Aquadex SmartFlow System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.About the BIG4 ConferenceLake Street Capital Markets will host its 4th annual Best Ideas Growth (BIG4) Conference on a virtual platform, showcasing many interesting and dynamic public growth companies. Executives from approximately 90 publicly traded companies will meet institutional investors in an interactive, one-on-one format. This is an invitation-only event attended by top institutional investors from across the country.Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about its participation in this conference. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our expectations regarding the potential impacts of the COVID-19 pandemic on our business operations, our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. CONTACT: CONTACTS INVESTORS: Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.com MEDIA: Jessica Stebing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com

  • GlobeNewswire

    CHF Solutions’ Physician-Led Webinar Concludes Fluid Overloaded Heart Failure Patients Benefit from Ultrafiltration

    EDEN PRAIRIE, Minn., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced key takeaways from a recent webinar, where Dr. John L. Jefferies discussed the use of precision medicine for the treatment of fluid overload in heart failure (HF) patients, including alternatives to diuretics, such as ultrafiltration using the Aquadex SmartFlow™ system. Clinically important observations made by Dr. Jefferies during the webinar include: * The impact of fluid overload on HF patients is significant. 90% of HF hospitalizations are due to signs and symptoms of fluid overload.1 * Common fluid overload treatment approaches such as diuretics are associated with mixed outcomes and adverse events. Studies have shown 42% of acutely decompensated HF patients either return to the emergency room, are re-hospitalized or die within 60 days of hospital discharge, regardless of diuretic strategy.2 * Ultrafiltration is an effective treatment strategy for patients with HF.  When compared to diuretics, there is a 53% reduction in the risk of rehospitalization among HF patients receiving ultrafiltration.3 * The use of ultrafiltration after cardiac surgery has been shown to improve cardiac performance, 4 reduce the duration of assisted ventilation5 and can reduce the need for blood transfusions.6“Ultrafiltration has continued to demonstrate efficacy in various clinical settings, and heart failure is a significant area where Aquadex™ has proven to be advantageous in the delivery of effective patient care,” said John Erb, CEO of CHF Solutions. “Dr. Jefferies’ experience provides valuable insights for heart failure clinicians and beyond. There are many patients who can benefit from ultrafiltration therapy and this educational webinar helps to ensure providers are equipped with knowledge of various treatment options for fluid overloaded patients.”Dr. Jefferies also discussed Aquadex-specific considerations and recommendations in regard to venous access, anticoagulation, ultrafiltration rate and Hematocrit (HCT) and SV02 monitoring.  Access this information and a white paper analysis by watching the webinar replay available on the company website and on CHF Solutions’ YouTube page.  Dr. Jefferies’ presentation will be a part of the company’s offerings at the 24th Annual Scientific Meeting of the Heart Failure Society October 3-5, 2020.Dr. Jefferies serves as Director of the Methodist University of Tennessee Cardiovascular Institute. He is a Professor of Pediatric Cardiology, Professor of Preventive Medicine, and a Research Member of St. Jude Children’s Research Hospital. Dr. Jefferies has published 200 peer-reviewed manuscripts and is the Lead Editor for two widely acclaimed textbooks.About CHF Solutions CHF Solutions, Inc. (CHFS) is a medical device company dedicated to changing the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow™ system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.About the Aquadex SmartFlow System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the treatment of fluid overload in patients with acute heart failure. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our expectations regarding the potential impacts of the COVID-19 pandemic on our business operations, our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 1. Costanzo MR, et al. J Am Coll Cardiol. 2017 May 16;69(19):2428-2445 2. Felker MG, et al. N Engl J Med 2011; 36:797-805. 3. Costanzo MR, et al. J Am Coll Cardiol. 2007;49(6):675-683 4. Sahoo, TK, et al. Indian J Thorac Cardiovas Surg. 2007 Jun;23(2): 116-124. 5. Luciani GB, et al. Circulation. 2001 Sep 18;104(12 Suppl 1): I253-I259 6. Sahoo, TK, et al. Indian J Thorac Cardiovas Surg. 2007 Jun;23(2): 116-124.CONTACTS INVESTORS:Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.comMEDIA:Jessica Stebing Health+Commerce 260-336-6202 jstebing@healthandcommerce.com